COVIDOCRECHE: COVID-19 Infection and Transmission in Exposed, Confined and Community-based Infants

Sponsor
Assistance Publique - Hôpitaux de Paris (Other)
Overall Status
Completed
CT.gov ID
NCT04413968
Collaborator
(none)
600
11
1
4
54.5
13.6

Study Details

Study Description

Brief Summary

According to epidemiological models, the seroprevalence of SARS-CoV-2 infection in Île-de-France as of 11 May was between 10 and 15%. Preliminary data on the number of professionals evicted from nurseries on suspicion of COVID-19 (on clinical grounds) seem to be of the same order of magnitude, but need to be confirmed by a biological technique. Children would be susceptible to infection but often asymptomatic.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Rapid detection test
  • Diagnostic Test: Nasopharyngeal swab
  • Diagnostic Test: Stool collection
N/A

Detailed Description

SARS-CoV-2, an emerging respiratory virus of the coronavirus family, is responsible for a global pandemic of which Europe has become the epicentre. Infection with the virus causes a disease called COVID-19, whose expression most often includes cough, fever, fatigue, myalgia, anosmia, ageusia and gastrointestinal symptoms, and which can be complicated by severe pneumonia requiring resuscitation and which can lead to death. Morbidity and mortality are clearly age-related and while illness and hospitalisations occur in all age groups, deaths occur mostly in the older age groups.

In the absence of curative treatment and vaccination, the only real measures capable of slowing the progression of the disease are large-scale social distancing measures. In analogy to community-based viral epidemics such as seasonal influenza, children were initially considered a potential vector of transmission, which led to the preventive measure of school closures. In France, this closure came into force on 14 March 2020.

Children are considered to be little affected by the coronavirus-19 epidemic because even if screening strategies differ, they represent less than 3% of the cases confirmed in the various studies.

In a period of confinement and reduction in the number of children cared for, in a crèche for children of healthcare workers, in a context of proximity and high risk of cross transmission, the frequency of symptomatic and asymptomatic forms of SARS-Cov-2 in children and staff would be comparable to the general population.

We hypothesize a susceptibility to infection in children but low transmission, which should lead to a cumulative prevalence of infection among daycare staff comparable to that obtained in a sample of professionals who do not come into contact with children in their work (here hospital laboratory and administrative staff).

Study Design

Study Type:
Interventional
Actual Enrollment :
600 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
Cross-sectional, multi-center, non-randomized studyCross-sectional, multi-center, non-randomized study
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Contamination and Transmission of the SARS-CoV-2 Virus in Exposed, Confined and Community-based Infants: A Cross-sectional, Multicentre, Interventional Seroprevalence Study
Actual Study Start Date :
Jun 2, 2020
Actual Primary Completion Date :
Jul 2, 2020
Actual Study Completion Date :
Oct 2, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: Interventional

nasopharyngeal and blood sample

Diagnostic Test: Rapid detection test
Rapid serological test by taking 3 drops of blood from the fingertip via the TDR device (rapid detection test) for children, supervising nursery staff and hospital laboratory and administrative staff

Diagnostic Test: Nasopharyngeal swab
Posterior nasopharyngeal swabbing in children

Diagnostic Test: Stool collection
Stool collection in children

Outcome Measures

Primary Outcome Measures

  1. Assess the serological status/rate of past infections in the children of priority staff in the nursery during the containment period [Day of intervention (1 day)]

    Proportion of children with a positive rapid serological test (presence of anti-SARS-CoV2 antibodies (IgM or IgG)).

Eligibility Criteria

Criteria

Ages Eligible for Study:
1 Month and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
Population 1 :
  • Children of priority staff welcomed in the crèche during the period of confinement, i.e. from 15 March to 9 May, regardless of the length of time they are in the crèche during this period and their "symptomatic or not" status during this period or on the day of inclusion.

  • Consent of the holders of parental authority

  • Affiliated to a social security system or entitled person

Population 2 :
  • Nursery staff, regardless of their status/occupation and having had contact with the children during the period of confinement regardless of how long they have been in the nursery during this period and their "symptomatic or not" status during this period or on the day of inclusion.

  • Consent to participate

  • Affiliated to a social security system or entitled person

Population 3 :
  • Hospital staff not exposed to patients and/or children, with or without children in day care, working in the bacteriology, biochemistry and biological haematology laboratories or in an administrative department of the participating hospitals.

  • Affiliated to a social security system or entitled person

Exclusion Criteria:
Population 1 :
  • Refusal to sign consent by parents

  • Clinical condition requiring urgent medical assessment (attending physician or transfer to paediatric emergency)

Population 2 and 3 :
  • Refusal to sign consent for staff

  • Clinical condition requiring urgent medical evaluation

Contacts and Locations

Locations

Site City State Country Postal Code
1 Hopital Avicenne Bobigny France 93000
2 Hôpital Jean Verdier - Service de Pédiatrie Bondy France 93143
3 Hôpital Jean Verdier Bondy France 93143
4 Hôpital Antoine béclère Clamart France 92140
5 Hôpital Louis Mourier Colombes France 92700
6 CH intercommunal de Créteil Créteil France 94000
7 Hôpital Andé Mignot Le Chesnay France 78150
8 Hôpital Trousseau Paris France 75012
9 Hôpital Robert debré Paris France 75019
10 CHU de Rouen Rouen France 76000
11 Hôpital Annecy Genevois Épagny France

Sponsors and Collaborators

  • Assistance Publique - Hôpitaux de Paris

Investigators

  • Principal Investigator: Eric LACHASSINNE, MD, Assistance Publique - Hôpitaux de Paris

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier:
NCT04413968
Other Study ID Numbers:
  • APHP200587
  • 2020-A01540-39
First Posted:
Jun 4, 2020
Last Update Posted:
Oct 26, 2020
Last Verified:
May 1, 2020
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Assistance Publique - Hôpitaux de Paris
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 26, 2020